Related Experiment Video
Updated: Sep 11, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Drug-Coated Balloons for Coronary Interventions: A Focused Review.
Akash H Patel1, Mark W Abdelnour1, Antonio H Frangieh1
1University of California Irvine, Irvine, California, US.
Drug-coated balloons (DCBs) offer a promising alternative to stenting for coronary artery disease (CAD). These devices deliver drugs to reduce restenosis, showing effectiveness in various lesion types and potentially reducing risks associated with metallic implants.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomaterials Science
Background:
- Catheter-based interventions have transformed coronary artery disease (CAD) treatment.
- Drug-coated balloons (DCBs) represent an advancement, delivering antiproliferative drugs to the vessel wall.
- DCBs offer an alternative to permanent metallic implants, potentially reducing thrombotic risks.
Purpose of the Study:
- To review the evolution and clinical applications of DCBs in CAD management.
- To focus on DCBs' role in treating in-stent restenosis (ISR), de novo lesions, and complex coronary anatomies.
- To evaluate DCBs as an alternative to traditional stent-based therapies.
Main Methods:
- Literature review of studies on DCB technology and clinical outcomes in CAD.
- Analysis of DCB efficacy in various lesion subsets, including ISR, small vessels, bifurcations, and long diffuse lesions.
- Comparison of DCB performance against drug-eluting stents in relevant patient populations.
Main Results:
- DCBs have demonstrated effectiveness in treating ISR.
- Recent studies show expanded applications for DCBs in complex lesions and small vessels.
- DCBs have shown non-inferiority to drug-eluting stents in specific patient groups and lesion types.
- Challenges include potential for coronary dissection and need for optimal lesion preparation.
Conclusions:
- DCBs show strong potential for reducing restenosis and improving long-term outcomes in CAD.
- They offer a versatile, effective, and potentially safer approach compared to traditional stenting.
- Further research is needed to optimize DCB use in off-label indications.
More Related Videos
06:39Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
Published on: February 18, 2020
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Cardiovascular Drugs: Classification based on Therapeutic Indications
Acute Coronary Syndrome IV: Interprofessional Care